Related Experiment Videos
Desmethylimipramine overdose: nonlinear kinetics in a slow hydroxylator
Therapeutic Drug Monitoring
|January 1, 1985
Summary
Desmethylimipramine (DMI) overdose was analyzed using HPLC. Slow hydroxylation and nonlinear kinetics in a patient affected DMI and metabolite levels, impacting drug elimination.
Area of Science:
- Pharmacology
- Clinical Toxicology
- Pharmacokinetics
Background:
- Desmethylimipramine (DMI) is a tricyclic antidepressant.
- Understanding DMI metabolism and elimination is crucial for managing overdose cases.
- Individual patient factors, such as genetic variations in drug metabolism, can significantly influence drug pharmacokinetics.
Observation:
- A case of desmethylimipramine (DMI) overdose was reported.
- Plasma concentrations of DMI and its primary metabolite, 2-hydroxydesmethylimipramine (2-OH-DMI), were analyzed.
- High-performance liquid chromatography with fluorescence detection was employed for plasma analysis.
Findings:
- DMI elimination kinetics followed Michaelis-Menten (nonlinear) kinetics.
- The patient was identified as a slow hydroxylator based on debrisoquine phenotyping.
- A significant difference in plasma concentrations of DMI and 2-OH-DMI was observed in this patient.
Implications:
- Nonlinear kinetics and slow hydroxylation likely contributed to the observed DMI and metabolite levels.
- This case highlights the importance of considering individual metabolic capacity in DMI toxicity.
- Pharmacokinetic variability can impact the clinical presentation and management of DMI overdose.